Viking Therapeutics (VKTX) Common Equity (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Common Equity data on file, last reported at $501.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 40.74% year-over-year to $501.9 million; the trailing twelve-month figure through Mar 2026 stood at $501.9 million (down 40.74% YoY), and the FY2025 full-year result was $639.1 million, down 27.4% from the prior year.
• Common Equity retreated to $501.9 million in Q1 2026, from $639.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $933.9 million in Q1 2024 to a low of $134.1 million in Q1 2023.
• A 5-year average of $530.8 million and a median of $501.9 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 596.6% in 2024 and plunged 40.74% in 2026, its largest moves.
• Tracing VKTX's Common Equity over 5 years: stood at $145.3 million in 2022, then jumped by 139.76% to $348.4 million in 2023, then jumped by 152.65% to $880.3 million in 2024, then retreated by 27.4% to $639.1 million in 2025, then dropped by 21.46% to $501.9 million in 2026.
• Business Quant data shows VKTX's Common Equity at $501.9 million in Q1 2026, $639.1 million in Q4 2025, and $713.0 million in Q3 2025.